Jan. 12 at 11:39 AM
$CMMB
Diseases With Elevated CCL24 Associated With Progression/Severity
1. Systemic Sclerosis (Scleroderma)
What it is: A chronic autoimmune connective-tissue disease marked by fibrosis of skin and internal organs.
CCL24 relevance: Serum levels are elevated in patients and predict disease severity and progression, especially interstitial lung disease (ILD) and mortality. Higher baseline CCL24 correlates with greater lung function decline and severe vascular/fibrotic manifestations.
2. Primary Sclerosing Cholangitis (PSC)
What it is: A chronic liver disease causing inflammation and fibrosis of bile ducts, often progressive to cirrhosis.
CCL24 relevance: Elevated expression in liver tissue and serum correlates with fibrosis severity and chronic inflammation. CCL24 is implicated in progression of biliary injury and represents a therapeutic target.
3. Metabolic Dysfunction-Associated Liver Diseases (MASLD / MASH)
What they are: Spectrum from simple steatosis (MASLD) to steatohepatitis (MASH) with inflammation and fibrosis.
CCL24 relevance: Serum levels are elevated in patients with more severe fibrosis and in experimental models, correlating with progressive liver injury.
4. Idiopathic Pulmonary Fibrosis (IPF) / Fibrotic Lung Disease
What it is: A progressive lung disease with scarring of lung tissue.
CCL24 relevance: Elevated CCL24 expression in lung tissue is associated with fibrosis severity and progression, similar to systemic sclerosis–associated ILD.
🦠 Inflammatory & Immune-Mediated Conditions
5. Juvenile Idiopathic Arthritis (JIA)
What it is: A chronic inflammatory arthritis in children.
CCL24 relevance: Synovial fluid CCL24 levels were higher in patients who later required advanced therapies, suggesting association with disease persistence/severity.
6. Asthma & Type 2 Airways Diseases (e.g., AERD)
What it is: Allergic, eosinophil-driven airway inflammation.
CCL24 relevance: Elevated CCL24 (eotaxin-2) associates with airway inflammation in aspirin-exacerbated respiratory disease and asthma phenotypes, contributing to disease activity and progression of inflammation.
(Note: CCL24 may be elevated in chronic asthma and related airway disease but not always directly predictive of long-term progression in all cohorts.)
🍃 Other Conditions Linked to CCL24 Pathways
These conditions show associations with elevated CCL24 expression or involvement in pathophysiology, though evidence linking levels to disease progression specifically (e.g., progression rate or prognosis) is more preliminary:
7. Rheumatoid Arthritis and Other Arthritides
CCL24 is found elevated in synovial fluid and may be part of inflammatory cascades linked to joint disease, but its role in predicting progression is not fully established.
8. Chronic Liver Diseases Beyond PSC/MASH
Conditions like primary biliary cirrhosis show high CCL24 expression, potentially linked to fibrosis.
9. Atherosclerosis and Cardiovascular Disease
Preclinical models suggest CCL24 contributes to vascular inflammation and plaque progression, though clinical validation is ongoing.
10. Cancer/Tumor Microenvironment
CCL24 expression is elevated in several tumors (colon cancer, hepatocellular carcinoma, cutaneous T-cell lymphoma) affecting macrophage polarization, angiogenesis, and progression in preclinical studies.
11. Eosinophilic and Allergic Inflammatory States
Conditions with strong Th2/eosinophil involvement, such as chronic rhinosinusitis with nasal polyps, may exhibit increased CCL24, though not all studies show it as a progression marker.
📌 Summary: Why CCL24 Matters in Disease Progression
Fibrosis & chronic inflammation: Elevated CCL24 is most consistently linked to worsening fibrosis and marked progression in diseases like systemic sclerosis, PSC, and MASLD/MASH.
Inflammatory severity: In conditions with Th2/Eos pathway activation, CCL24 reflects overall immune activation and may correlate with severity.
Predictive biomarker potential: In systemic sclerosis and some liver diseases, CCL24 has demonstrated utility as a biomarker of disease progression or poor prognosis
Nebokitug has shown to reduce/neutralize CCL24 which attributes to fibrosis--this monoclonal AB potential goes way beyond (PSC and SSC) and could play an important role in treating other aliments.. IMO this would be an attractive molecule for a big pharma to own outright.
